Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Esserman

Showing results (121-130 of 143) with videos related to

Pageof 15
Sort By:
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 28, 2026
Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health NetworkKatherine Leggat-Barr, Tomiyuri Lewis, Jeffrey A Tice, et al.
Nature Reviews. Endocrinology|August 17, 2023
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classificationKen K Y Ho, Ursula B Kaiser, Phillippe Chanson, et al.
Annals of Surgical Oncology|February 13, 2025
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical TrialJudy C Boughey, Hongmei Yu, Kayla Switalla, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Cancer Cell|December 13, 2006
Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesKoei Chin, Sandy DeVries, Jane Fridlyand, et al.
Lancet (London, England)|June 24, 2010
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialJayant S Vaidya, David J Joseph, Jeffrey S Tobias, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
The Lancet. Respiratory Medicine|July 26, 2021
Advancing precision medicine for acute respiratory distress syndromeJeremy R Beitler, B Taylor Thompson, Rebecca M Baron, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Pageof 15

Showing results (121-130 of 143) with videos related to

Sort By:
Pageof 15
JCO Precision Oncology|September 11, 2020
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIALJulia D Wulfkuhle, Christina Yau, Denise M Wolf, et al.
Breast Cancer Research and Treatment|January 28, 2026
Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health NetworkKatherine Leggat-Barr, Tomiyuri Lewis, Jeffrey A Tice, et al.
Nature Reviews. Endocrinology|August 17, 2023
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classificationKen K Y Ho, Ursula B Kaiser, Phillippe Chanson, et al.
Annals of Surgical Oncology|February 13, 2025
Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical TrialJudy C Boughey, Hongmei Yu, Kayla Switalla, et al.
Breast Cancer Research and Treatment|January 6, 2026
RISE UP for breast cancer 2024: conference highlights & takeawaysTaylor Glatt, Katherine Leggat-Barr, Nandini Seth, et al.
Cancer Cell|December 13, 2006
Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesKoei Chin, Sandy DeVries, Jane Fridlyand, et al.
Lancet (London, England)|June 24, 2010
Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialJayant S Vaidya, David J Joseph, Jeffrey S Tobias, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2013
Developing safety criteria for introducing new agents into neoadjuvant trialsAngela DeMichele, Donald A Berry, JoAnne Zujewski, et al.
The Lancet. Respiratory Medicine|July 26, 2021
Advancing precision medicine for acute respiratory distress syndromeJeremy R Beitler, B Taylor Thompson, Rebecca M Baron, et al.
Cell Reports. Medicine|November 7, 2024
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerMichael J Campbell, Denise M Wolf, Christina Yau, et al.
Pageof 15